Abstract | BACKGROUND: METHODS: Literature searches, systematic reviews and assessments about the structure, distribution, regulation and novel functions of ACP5 were performed in this review from PubMed and Medline databases. RESULTS: Studies demonstrate that RANKL can increase the expression of ACP5 through NFATc1 and c-Fos to accelerate osteoclastogenesis, which also can be regulated by many regulators. Based on the aforementioned information, it is shown that ACP5, together with the phosphatase activity, can medicate the progression and development of human genetic diseases and cancer. CONCLUSION: As a novel target, ACP5 plays a critical role in preventing, monitoring and treating various kinds of tumors, as well as accelerating the development of a promising therapeutic strategy for human genetic diseases. However, the explicit mechanism between ACP5 and cancer is not so clear. It is necessary and significant for us to pay more in-depth attention.
|
Authors | Xin Ren, Wen-Hua Shan, Lu-Lu Wei, Chan-Chan Gong, Dong-Sheng Pei |
Journal | Anti-cancer agents in medicinal chemistry
(Anticancer Agents Med Chem)
Vol. 18
Issue 8
Pg. 1082-1090
( 2018)
ISSN: 1875-5992 [Electronic] Netherlands |
PMID | 29637867
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | Copyright© Bentham Science Publishers; For any queries, please email at [email protected]. |
Chemical References |
- ACP5 protein, human
- Tartrate-Resistant Acid Phosphatase
|
Topics |
- Humans
- Neoplasms
(metabolism)
- Protein Conformation
- Tartrate-Resistant Acid Phosphatase
(chemistry, metabolism)
|